What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Stendra® (avanafil) tablets

Approval Date: Jun 2024

Note: First-Time Generic

Indicated for the treatment of erectile dysfunction

hello world!

Pyzchiva® (Ustekinumab-ttwe) injection

Approval Date: Jun 2024

Note: Biosimilar

A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis

hello world!

Chewtadzy (tadalafil) chewable tablets

Approval Date: Jun 2024

Note: New Product

A new chewable tablet indicated for the treatment of erectile dysfunction, and the signs and symptoms of benign prostatic hyperplasia

hello world!

Descovy® (emtricitabine and tenofovir alafenamide) tablets

Approval Date: May 2024

Note: First-Time Generic

Indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents

hello world!

Entresto® (sacubitril and valsartan) tablets

Approval Date: May 2024

Note: First-Time Generic

Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure

hello world!

Rezenopy (naloxone hydrochloride) nasal spray

Approval Date: Apr 2024

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression

hello world!

Selarsdi (Ustekinumab-aekn) injection

Approval Date: Apr 2024

Note: Biosimilar, New Product

A biosimilar of Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis

hello world!

Risvan® (risperidone) for extended-release injectable suspension

Approval Date: Mar 2024

Note: New Product

A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia

hello world!

Winrevair (sotatercept-csrk) injections

Approval Date: Mar 2024

Note: Biologic, New Product

A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events

hello world!

Opsynvi® (macitentan and tadalafil) tablets

Approval Date: Mar 2024

Note: New Product

Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both

hello world!

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmagnifiermenucross-circle